January 30

Corporate Welfare Runs Amok – NYT Editorial

Corporate Welfare Runs Amok – NYT Editorial

Sun, 30 Jan 2005

The administration has gone another step toward doing away with corporate taxes – by offering a “tax holiday” to America’s richest multinationals. The 35% corporate tax rate is being winnowed down to the “puny rate” of 5.25% for corporations that bring their foreign profits home. The administration is offering a reward to corporations who have not been paying taxes as other corporations do.

Who do you think are the major corporate benficiaries?

Why the “cash rich” pharmaceutical companies who shelter their foreign profits to avoid taxes: Merck has $15 billion in sheltered profits; Johnson & Johnson, $11 billion; Shering-Plough, $9.4 billion; Eli Lilly, $8 billion…. It is estimated that by the end of 2005 between $100 billion and $500 billion will be “repatriated.”

The company’s gain is the US Treasury’s loss. This giveaway will allow companies to spend the money to buy other companies – resulting, no doubt, in job layoffs, as corporate acquisitions usually do. It will also provide even larger legal defense funds for drug companies whose unconscionable marketing practices – such as concealing hazardous drug effects while advertising the drugs’ safety–have resulted in preventable deaths. What possible justification can there be for the government to reward – and thereby to encourage–corporate crimes?

The Times editorial notes: “All it will really do is what the drafters probably intended all along – further erode the nation’s corporate tax base and impugn the system’s integrity, in that way building a case for eliminating corporate taxes altogether. That is a lousy way to make policy.”

Contact: Vera Hassner Sharav


THE NEW YORK TIMES January 30, 2005 EDITORIAL Corporate Welfare Runs Amok

Earlier this month, Johnson & Johnson became one of the first major American corporations to sign on for a one-year “tax holiday” – a government-sponsored opportunity for American multinationals to bring their foreign profits back to the United States at a puny tax rate of 5.25 percent, compared with the normal corporate rate of 35 percent. Johnson & Johnson intends to repatriate $11 billion. And that is just the beginning of what is shaping up to be an unprecedented government giveaway.

The drug giant Schering-Plough has announced a coming $9.4 billion repatriation, and Eli Lilly has announced one for $8 billion. Many other cash-rich companies, especially in pharmaceuticals and technology, are expected to follow suit. Pfizer is considering whether to repatriate $29 billion in untaxed foreign profits; Hewlett-Packard has $14.5 billion eligible for repatriation; Intel has $6 billion. By the end of 2005, an estimated $100 billion to $500 billion will have found its way home. Over the long run, Congress’s Joint Committee on Taxation projects that the holiday will allow companies to avoid $3.3 billion in taxes, an estimate that many tax experts think is low.

The nation’s corporate tax rules – combined with spotty enforcement by an underfunded and outmuscled Internal Revenue Service – provide strong incentives for American companies to shift their profits from the United States to low-tax havens, such as Ireland and Luxembourg. Once there, the profits are allowed to grow untaxed by the United States until they are repatriated. That tax deferral is a hugely munificent gesture – as if the country’s biggest businesses had been granted their own special I.R.A.’s.

But it wasn’t enough for many companies that have piled up excess cash abroad. The Homeland Investment Coalition, a roster of dozens of America’s largest corporations, lobbied vigorously – and successfully – for a tax holiday before deigning to repatriate their overseas profits.

Congress’s ostensible purpose for allowing the holiday is to unleash a flood of money for job creation, hence the name of the law that includes the holiday – the American Jobs Creation Act of 2004. But few of the approved uses for the repatriated funds – such as debt redemption, advertising and a catchall category of “financial stabilization” – will lead directly, if at all, to more jobs. One approved use – the ability to spend the money to buy other companies – would be more likely to create layoffs, as corporate acquisitions usually do.

Companies can also use the money to help pay legal liabilities, which could prove to be a big boon for companies like the drug maker Merck, which is sitting on some $15 billion in untaxed foreign profits and faces an estimated $18 billion in potential claims arising from the Vioxx debacle. Multinationals cannot use the repatriated profits to pay dividends to shareholders, buy back their own stock or pay executives. But because companies have a lot of flexibility in financing their activities, they will generally be able to use the money as they see fit while still meeting the letter of the law.

So the tax holiday blesses rather than curbs tax avoidance and is structured to encourage little if any new domestic economic activity. It establishes a horrible precedent by encouraging companies to leave profits abroad in anticipation of future holidays. It makes fools of companies that have routinely repatriated foreign profits at the full corporate tax rate. And it disadvantages American companies that have no foreign presence and thus no opportunity to reap profits at a discounted tax rate.

All it will really do is what the drafters probably intended all along – further erode the nation’s corporate tax base and impugn the system’s integrity, in that way building a case for eliminating corporate taxes altogether. That is a lousy way to make policy. Reforms to the corporate tax system must be debated on their merits, not under cover of some phony label like “job creation.”

Copyright 2005 The New York Times Company

FAIR USE NOTICE: This may contain copyrighted (© ) material the use of which has not always been specifically authorized by the copyright owner. Such material is made available for educational purposes, to advance understanding of human rights, democracy, scientific, moral, ethical, and social justice issues, etc. It is believed that this constitutes a ‘fair use’ of any such copyrighted material as provided for in Title 17 U.S.C. section 107 of the US Copyright Law. This material is distributed without profit.

Subscribe To Our Newsletter!

Sign up and be the first to find out the latest news and articles about what's going on in the medical field.

You may also like

November 21, 2023

Vera Sharav is joining Christine Anderson as special guest for the Make It Your Business event in

Read More
Vera Sharav Joins Christine Anderson for Make It Your Business – Dec 4, 2023 in New Jersey

November 21, 2023

Vera Sharav is premiering the movie Never Again is Now Global in New York City, December 1.

Read More
Never Again is Now Global – Premiere Screening – Dec 1, 2023 in New York City